Short- and long-term outcomes of the titanium-NO stent registry

Mosseri, Morris; Tamari, Israel; Plich, Michael; Hasin, Yonathan; Brizines, Mark; Frimerman, Aaron; Miller, Hilton I.; Jafari, Jamal; Guetta, Victor; Solomon, Mivi; Lotan, Chaim

doi:10.1016/j.carrev.2005.04.004

Cited by 30 publications

(25 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It demonstrated a high angiographic and clinical success rate of Titan Ò stent implantation, with a low MACE rate at 6-month follow-up. Several previous studies have reported an excellent outcome of BAS in unselected patient populations [16][17][18][19]. The results of the current registry would serve to support their observations and extend this favorable outcome to patients with DM.…”

Section: Discussionsupporting

confidence: 67%

“…The safety of titanium-nitride-oxide-coated stents (Titan Ò ) has been confirmed in several studies in real-life unselected populations [16][17][18][19][20]. Interestingly, several prospective studies have demonstrated an even 'better' outcome with BAS in comparison with paclitaxel-eluting stents in the real-world setting of high-risk patients and complex (type B and C) coronary lesions [21,22], and in patients with acute myocardial infarction [23,24].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Titanium-nitride-oxIde-coated stents multicenter registry in diaBEtic patienTs: the TIBET registry

et al. 2011

View full text Add to dashboard Cite

We sought to explore the immediate clinical and angiographic results of the Titan(®) stent implantation in diabetic patients, as well as the major adverse cardiac events (MACE) at 6-month follow-up. We enrolled 156 consecutive diabetic patients admitted to undergo percutaneous intervention for at least one significant (50%) coronary lesion. All lesions were treated with the Titan(®) stent implantation according to the contemporary interventional techniques. Patients were prospectively followed-up for at least 6 months. The primary endpoint was MACE at 6-month follow-up [cardiac death, myocardial infarction (MI), or target lesion revascularization (TLR)]. Secondary endpoints included angiographic and clinical procedural success, in-hospital MACE, TLR at 6-month follow-up, and stent thrombosis. The mean age was 66.7 ± 9.6 years, (68.4% males). A total of 197 Titan(®) stents were implanted in 163 lesions. Direct stenting was performed in 45.2% of the cases. The mean stent diameter was 3.1 ± 0.61 mm, and the mean length was 18.0 ± 8.9 mm. Average stent deployment pressure was 13.9 ± 4.2 bars. Angiographic procedural success was achieved in 154 (98.7%) cases, and clinical procedural success was achieved in 153 (98.1%) cases. One patient developed in-hospital non-Q-wave MI following the procedure. Clinical follow-up was completed in 155 (99.4%) patients. Three patients (1.9%) died of a cardiac or unknown cause, and two (1.3%) developed MI. TLR was performed in 11 patients (7.1%). Cumulative MACE at 6-month follow-up occurred in 16 (10.3%) patients. No patient suffered stent thrombosis. Titan(®) stent implantation in diabetic patients achieves an excellent immediate clinical and angiographic outcome, with a low incidence of MACE at mid-term follow-up.

show abstract

Section: Discussionsupporting

confidence: 67%

Section: Introductionmentioning

confidence: 99%

Titanium-nitride-oxIde-coated stents multicenter registry in diaBEtic patienTs: the TIBET registry

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Metallic sheaths coated with titanium nitride or titanium oxide demonstrated higher endothelial cell density values on their surfaces in comparison with those without such coatings, suggesting that the use of stents covered with these coatings may accomplish earlier complete endothelialization [28]. The safety of the titanium-nitride-oxide-coated Titan2 V R BAS has been validated in several clinical trials, both in unselected populations and in the most complex ones such as diabetic patients and those presenting with acute MI [13][14][15][16]. Yet, PCI in small coronary arteries still represents an obvious challenge to the interventional cardiologist.…”

Section: Titanium-nitride-oxide Basmentioning

confidence: 99%

“…The safety of titanium-nitride-oxide-coated stents (Titan2 V R , Hexacath, Paris, France) has been confirmed in several studies in real-life unselected populations [12][13][14][15][16]. Interestingly, several randomized studies have demonstrated an even 'better' outcome with BAS in comparison with Paclitaxel-eluting stents in the realworld setting of high-risk patients and complex (type B and C) coronary lesions [17,18], as well as in patients with acute myocardial infarction (MI) [19,20].…”

Section: Introductionmentioning

confidence: 99%

The EXTREME registry: Titanium‐nitride‐oxide coated stents in small coronary arteries

Valdesuso

Karjalainen

Garcı́a

et al. 2010

Cathet Cardio Intervent

View full text Add to dashboard Cite

show abstract

“…Ti-nitride-oxide coating on 316L SS was biologically inert, reducing platelet and fibrinogen deposition, and neointimal hyperplasia 32 . Promising results were reported in clinical trials by the Titan stent (Hexacath, France) using this coating 33,34 . Moreover, Ti-based Ta and niobium alloys showed excellent haemocompatibility 35 , indicating they have potential applications for stents.…”

Section: Tamentioning

confidence: 99%